Amy DuRoss – VJRegenMed

What can the field learn from the COVID-19 pandemic?

Mon, 05 Jul 2021 13:47:08 +0000

Amy DuRoss, Co-Founder & CEO, Vineti, San Francisco, CA, discusses the lessons that the field of cell and gene therapy can learn from the COVID-19 pandemic. The accelerated development and approval of vaccines for COVID-19 has demonstrated the positive impact of cross collaboration within the industry. The use of mRNA technology in vaccine development has also enhanced understanding and infrastructure, and these advances could be leveraged in the field of cell and gene therapy such as through the use of mRNA-based boosters for CAR T-cell therapies. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>

Supply chain management & automation

Mon, 05 Jul 2021 13:47:08 +0000

Amy DuRoss, Co-Founder & CEO, Vineti, San Francisco, CA, describes the Personalized Therapy Management (PTM) platform, enterprise software that aims to address supply chain challenges and support the manufacturing and commercialization of cell and gene therapies. PTM aims to help manufacturers efficiently coordinate and automate chain of custody and chain of identity, ensuring personalized cell and gene therapies reach the right patients at the right time. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>

International collaboration in advanced therapies

Mon, 05 Jul 2021 13:47:08 +0000

Amy DuRoss, Co-Founder & CEO, Vineti, San Francisco, CA, explains that the scientific community’s response to the COVID-19 pandemic has demonstrated the importance of international collaboration and harmonization, and highlights this as a key learning opportunity for the field of advanced therapies. Exciting technological advances and the emergence of organizations that support the industry and offer the ability to connect all stakeholders, including manufacturers, academics and patients, are expected to help to drive standardization and industrialization within the field, and ultimately, improve patient access to novel therapies in the future. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>

Tackling challenges in industry standardization

Sat, 03 Jul 2021 09:00:54 +0000

Amy DuRoss, Co-Founder & CEO, Vineti, San Francisco, CA, highlights that despite the exciting pace of scientific discovery within the field of cell and gene therapy, it is now important for the industry to implement standardized and streamlined processes and technologies in order to support advancement and manufacturing scale out, while ensuring patient safety and minimizing costs. She describes a range of challenges that need to be addressed including the standardization of chain of identity and product labelling across different territories. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.

]]>